Chong Kun Dang Pharmaceutical Corp.
Symbol: 185750.KS
KSC
101200
KRWMarktpreis heute
6.4696
P/E-Verhältnis
-0.0542
PEG-Verhältnis
1.29T
MRK Kapital
- 0.01%
DIV Rendite
Chong Kun Dang Pharmaceutical Corp. (185750-KS) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 365065.3 | 155861.2 | 187332.6 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 145418.9 | 38444.3 | 55519.9 | |||||||||||
balance-sheet.row.net-receivables | 0 | 311468.6 | 287306.6 | 234703.7 | |||||||||||
balance-sheet.row.inventory | 0 | 261431.9 | 270081.5 | 224722.9 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 8606.1 | 365.5 | 20387.9 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 946571.9 | 713614.8 | 667147.2 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 319787.1 | 310697.4 | 298909.7 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 52527.1 | 26953 | 20805.5 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 52527.1 | 26953 | 20805.5 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 67179.1 | 5565.5 | -22146.7 | |||||||||||
balance-sheet.row.tax-assets | 0 | 14213.2 | 6208.6 | 2350.3 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 2150.1 | 61843.5 | 79634.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 455856.6 | 411268 | 379552.9 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 1402428.4 | 1124882.8 | 1046700.1 | |||||||||||
balance-sheet.row.account-payables | 0 | 183938.8 | 145436.3 | 129327.4 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 184767.4 | 124445.5 | 102091.4 | |||||||||||
balance-sheet.row.tax-payables | 0 | 43938.2 | 29026.4 | 18701.1 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 30000 | 111292.6 | 134962.3 | |||||||||||
Deferred Revenue Non Current | 0 | 1484.8 | 6438.3 | 5982 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 134996.6 | 98922.3 | 20691.5 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 75327.4 | 129380.9 | 160660.6 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 4996.5 | 1694.2 | 3470.5 | |||||||||||
balance-sheet.row.total-liab | 0 | 586793.3 | 503594 | 480890.4 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 31421.2 | 29970.1 | 28565.2 | |||||||||||
balance-sheet.row.retained-earnings | 0 | 218102.4 | 376370.8 | 302106.6 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 350829.8 | 276706.4 | 250156.9 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 215341.1 | -60654.3 | -14818.7 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 815694.5 | 622393.1 | 566010 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1402428.4 | 1124882.8 | 1046700.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | -59.3 | -1104.3 | -200.3 | |||||||||||
balance-sheet.row.total-equity | 0 | 815635.2 | 621288.8 | 565809.6 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 212598 | 44009.8 | 33373.2 | |||||||||||
balance-sheet.row.total-debt | 0 | 219763.9 | 235738.1 | 237053.8 | |||||||||||
balance-sheet.row.net-debt | 0 | 117.5 | 118321.2 | 105241.1 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 212521.2 | 79977.8 | 42356.5 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 36942.2 | 33597.7 | 27481.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 29681.8 | -77299.3 | -71568.7 | |||||||||||
cash-flows.row.account-receivables | 0 | -29559.7 | -51435.9 | -6926 | |||||||||||
cash-flows.row.inventory | 0 | -5980.3 | -54466.2 | -53770.6 | |||||||||||
cash-flows.row.account-payables | 0 | 38583.8 | 15824.5 | -15597.8 | |||||||||||
cash-flows.row.other-working-capital | 0 | 26638 | 12778.2 | 4725.7 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 39014.7 | 31458.4 | 14634.2 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -68806 | -53064.7 | -51844.4 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 451.6 | 142.1 | -3448.7 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -192468.2 | -57181.1 | -61266.4 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 89470 | 44375.6 | 21934.7 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 39.8 | 347.8 | 3815.5 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -171312.9 | -65380.3 | -90809.3 | |||||||||||
cash-flows.row.debt-repayment | 0 | -22714.6 | -0.3 | -896.2 | |||||||||||
cash-flows.row.common-stock-issued | 0 | -3335.3 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | -6025 | -1888.4 | -1935.3 | |||||||||||
cash-flows.row.dividends-paid | 0 | -11608.5 | -11238.8 | -10808.3 | |||||||||||
cash-flows.row.other-financing-activites | 0 | -16.5 | -3212.4 | 98778.7 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -43700 | -16339.8 | 85138.9 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -917.6 | -410.1 | 920.1 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 102229.4 | -14395.8 | 8153.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 219646.3 | 117416.9 | 131812.7 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 117416.9 | 131812.7 | 123659.1 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 318159.9 | 67734.5 | 12903.9 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -68806 | -53064.7 | -51844.4 | |||||||||||
cash-flows.row.free-cash-flow | 0 | 249353.9 | 14669.8 | -38940.5 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1669404.4 | 1488344.7 | 1343559.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 0 | 1014059.9 | 945705.3 | 847741.1 | |||||||||||
income-statement-row.row.gross-profit | 0 | 655344.5 | 542639.4 | 495818.3 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | -11694.4 | 139957.4 | 135069 | |||||||||||
income-statement-row.row.operating-expenses | 0 | 408657.6 | 432733.3 | 401059.6 | |||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1422717.5 | 1378438.7 | 1248800.7 | |||||||||||
income-statement-row.row.interest-income | 0 | 5789.3 | 2139 | 716.2 | |||||||||||
income-statement-row.row.interest-expense | 0 | 9271 | 6846.9 | 4029.9 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -5283.9 | -12741 | -14164.8 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | -11694.4 | 139957.4 | 135069 | |||||||||||
income-statement-row.row.total-operating-expenses | 0 | -5283.9 | -12741 | -14164.8 | |||||||||||
income-statement-row.row.interest-expense | 0 | 9271 | 6846.9 | 4029.9 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 36942.2 | 34919.3 | 18187.3 | |||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 0 | 246686.9 | 109906.1 | 94758.7 | |||||||||||
income-statement-row.row.income-before-tax | 0 | 241403 | 97165.1 | 80593.9 | |||||||||||
income-statement-row.row.income-tax-expense | 0 | 27995.7 | 17187.3 | 38237.4 | |||||||||||
income-statement-row.row.net-income | 0 | 212521.2 | 80953.4 | 42720.4 |
Häufig gestellte Frage
Wie hoch ist die Chong Kun Dang Pharmaceutical Corp. (185750.KS) Gesamtvermögen?
Chong Kun Dang Pharmaceutical Corp. (185750.KS) Gesamtvermögen ist 1402428435512.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist N/A.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.530.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist 19599.181.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.122.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 0.146.
Was ist der Chong Kun Dang Pharmaceutical Corp. (185750.KS) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist 212521171440.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 219763880100.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 408657610015.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 0.000.